Skip to main content

Login to North West London Pathology – consumables service

If you need a new account or you have a query about your order, please telephone the pathology call centre on 0203 313 5353.

If you have forgotten your password you can reset this yourself. Please click here if you have forgotten your password.

Results Line and Enquiries

0203 313 5353

Vedolizumab (anti-α4β7) Trough level

Category Immunology
Test background

Vedolizumab (Entyvio©) is a humanised IgG1 antibody approved for use in Crohn’s disease and ulcerative colitis. Vedolizumab inhibits the action of the mucosal trafficking α4β7 integrin and prevents migration of inflammatory T cells to the gut.

Response rates to vedolizumab are around 45% and early vedolizumab trough levels correlate with therapeutic outcomes in IBD. Dose escalation may induce or restore clinical response.

Vedolizumab levels are measured in serum taken from patients just before an infusion (trough) using an indirect ELISA coated with α4β7 integrin.

Clinical Indications

For the monitoring of drug trough levels in IBD patients treated with Vedolizumab.

Reference range

Negative (for patients never treated with vedolizumab)

Target trough levels for vedolizumab differ based on sampling time point (induction vs maintenance) and the target therapeutic outcome (clinical response vs endoscopic remission). Nassar IO, et al. Frontline Gastroenterol. 2022 Jan 24;13(5):430-435. doi: 10.1136/flgastro-2021-102032.

Sample & container required Serum (rust top) vacutainer
Sample volume 0.5ml
Sample collection

Samples should be taken just before the next infusion of drug (trough)

Turnaround time 4 weeks